BioCentury
ARTICLE | Company News

Stallergenes, Greer sales and marketing update

November 11, 2013 8:00 AM UTC

Stallergenes granted Greer exclusive, U.S. commercialization rights to Oralair, a sublingual therapy against five grass allergens. Stallergenes is eligible for regulatory and commercial milestones of up to $120 million, plus royalties and an undisclosed transfer price. Oralair is under review in the U.S., with a meeting of FDA's Allergenic Products Advisory Committee to discuss the BLA scheduled for Dec. 11. In October, Stallergenes declined to disclose when it expects a decision from FDA on Oralair. The product is approved in Europe, Argentina, Australia, Canada, New Zealand and Russia (see BioCentury, Oct. 28). ...